Multiple drug resistance (MDR), referring to the resistance of cancer cells to a broad
spectrum of structurally and mechanistically unrelated drugs across membranes, severely …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …

Resistance to chemotherapy remains one of the most significant obstacles to successful
cancer treatment. While inhibiting drug efflux mediated by ATP-binding cassette (ABC) …

The solute carrier (SLC) monocarboxylate transporter 1 (MCT1; SLC16A1) represents a
promising target for the treatment of cancer; however, the MCT1 modulator landscape is …

The major drawbacks of P-glycoprotein (P-gp) inhibitors at the clinical stage make the
development of new P-gp inhibitors challenging and desirable. In this study, we reported our …

Multidrug resistance (MDR) is one of the main reasons for the failure of tumor chemotherapy
and has a negative influence on the therapeutic effect. MDR is primarily attributable to two …

Multidrug resistance‐associated protein 1 (MRP1, ABCC1) is an ATP‐binding cassette
(ABC) transport protein. This efflux pump uses the energy of ATP hydrolysis to export …

Inspired by the structure of dysoxylactam A (DLA) that has been demonstrated to reverse P-
glycoprotein (P-gp)-mediated multidrug resistance (MDR) effectively, 61 structurally …

Molecular interactions of tumor cells with the microenvironment are regarded as onset of
chemotherapy resistance, referred to as cell adhesion mediated drug resistance (CAM-DR) …

Several ABC transporters (eg, ABCB1, ABCB4, ABCC1–5, ABCC10, ABCG2 and ABCG4)
are known to contribute to the phenomenon of cancer-related multidrug resistance (MDR)[1] …